Biomarkers and Diabetes

Issue20-banner-4

Dear Healthcare Professional!

In this issue of The MARK, we spotlight biomarker utility in managing patients with diabetes.

WHY INCLUDE GLYCOMARK WITH A1C?

A1C:

ADA Goal: <7%. Performed: Each 3 or 6 months

  • Up to 40% of patients with an A1C < 7% experience postprandial hyperglycemia and glycemic variability.1,2
  • Over 15% of A1C results can be affected by hematology conditions, medications, drugs, medical therapies, diseases, and other factors3

FACTORS KNOWN TO ALTER A1C3

Multiple-Factors-Alter-A1C-Results-forsite

GlycoMark:

Ref Range: ≥10 µg/mL. Performed: With A1C, 2-weeks post-treatment modifications, when control is questionable

  • Specifically indicates recent hyperglycemia and hyperglycemic excursions (1 to 2 weeks)4
  • More robustly reflects glycemic excursions, often in the postprandial state, than A1C5
  • Non-fasting blood test
  • Identifies patients that may benefit from closer diabetes management, including more diligent self-testing, CGM or treatment modifications
  • Strongly associated with higher rates of diabetes related complications, even after adjusting for A1C and other risk factors6-10)

WHY SUPPLEMENT GLUCOSE WITH GLYCOMARK?

Glucose:

ADA Goal: <180 mg/dL. Performed: (Ideally) Daily, and 2 hours postmeal

  • Not always reliably timed or performed11,12
  • May yield inaccurate results11,12

INCLUDE GLYCOMARK IN YOUR PATIENT WORKUP, TODAY!

References:
1Erlinger TP, Brancati FL. Diabetes Care. 2001 Oct;24(10):1734-8.
2Bonora E, et al. Diabetologia. 2006 May;49(5):846-54.
3Hirsch IB, et al. Diabetes Technol Ther. 2012 Nov;14(11):973-83; quiz 983.
4Dungan KM. Expert Rev Mol Diagn. 2008 Jan;8(1):9-19.
5American Diabetes Association. Medical Management of Type 2 Diabetes, 7th edition. 2012.
6Selvin E, et al. Clin Chem. 2014 Nov; 60(11): 1409–1418.
7Selvin E, et al. Diabetes 2016;65:201–208.
8Lee AK, et al. Diabetes Care 2017 Dec; 40(12): 1661-1667.
9Rawlings AM, et al. Diabetes Care 2017 Jul; 40(7): 879-886.
10Nowak N, et al. Diabetologia 2013 Apr; 56(4): 709–713.
11Erbach M, et al. J Diabetes Sci Technol. 2016;10:1161-1168.
12Klonoff DC, et al. J Diabetes Sci Technol. 2011;5:1529-1548.

The information contained herein is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark product insert for more information.